Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Ewa Gogola, Alexandra A. Duarte, Julian R. de Ruiter, et al.
Cancer Cell (2018) Vol. 33, Iss. 6, pp. 1078-1093.e12
Open Access | Times Cited: 301

Showing 1-25 of 301 citing articles:

State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilié, Chad Tang, Gordon B. Mills, et al.
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 81-104
Open Access | Times Cited: 967
A decade of clinical development of PARP inhibitors in perspective
Joaquı́n Mateo, Christopher J. Lord, Violeta Serra, et al.
Annals of Oncology (2019) Vol. 30, Iss. 9, pp. 1437-1447
Open Access | Times Cited: 568
PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 525
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose, Joshua T. Burgess, Kenneth J. O’Byrne, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 515
Targeting DNA damage response pathways in cancer
Florian J. Groelly, Matthew Fawkes, Rebecca A. Dagg, et al.
Nature reviews. Cancer (2022) Vol. 23, Iss. 2, pp. 78-94
Closed Access | Times Cited: 446
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin, Csaba Szabó
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 10, pp. 711-736
Closed Access | Times Cited: 403
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer, Haico van Attikum
Trends in Cell Biology (2019) Vol. 29, Iss. 10, pp. 820-834
Open Access | Times Cited: 373
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 359
PARP inhibitor resistance: the underlying mechanisms and clinical implications
He Li, Zhaoyi Liu, Nayiyuan Wu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 355
DNA Repair Pathways in Cancer Therapy and Resistance
Lanya Li, Yidi Guan, Xisha Chen, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 283
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
Madalena Tarsounas, Patrick Sung
Nature Reviews Molecular Cell Biology (2020) Vol. 21, Iss. 5, pp. 284-299
Open Access | Times Cited: 277
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Hyoung Kim, Haineng Xu, Erin George, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 263
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
Ke Cong, Min Peng, Arne Nedergaard Kousholt, et al.
Molecular Cell (2021) Vol. 81, Iss. 15, pp. 3128-3144.e7
Open Access | Times Cited: 241
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, et al.
EMBO Molecular Medicine (2018) Vol. 10, Iss. 12
Open Access | Times Cited: 222
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Hon Yan Kelvin Yip, Antonella Papa
Cells (2021) Vol. 10, Iss. 3, pp. 659-659
Open Access | Times Cited: 205
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
Isabella Faraoni, Grazia Graziani
Cancers (2018) Vol. 10, Iss. 12, pp. 487-487
Open Access | Times Cited: 196
Biomarker-Guided Development of DNA Repair Inhibitors
James M. Cleary, Andrew J. Aguirre, Geoffrey I. Shapiro, et al.
Molecular Cell (2020) Vol. 78, Iss. 6, pp. 1070-1085
Open Access | Times Cited: 195
Targeting replication stress in cancer therapy
Alexandre André Balieiro Anastácio da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 38-58
Closed Access | Times Cited: 192
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud, Antoîne Italiano
Cancers (2020) Vol. 12, Iss. 6, pp. 1502-1502
Open Access | Times Cited: 183
The expanding universe of PARP1-mediated molecular and therapeutic mechanisms
Dan Huang, W. Lee Kraus
Molecular Cell (2022) Vol. 82, Iss. 12, pp. 2315-2334
Open Access | Times Cited: 159
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
Timo Reisländer, Emilia Puig Lombardi, Florian J. Groelly, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 158
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Dae-Seok Kim, Cristel V. Camacho, W. Lee Kraus
Experimental & Molecular Medicine (2021) Vol. 53, Iss. 1, pp. 42-51
Open Access | Times Cited: 131
Current therapy and drug resistance in metastatic castration-resistant prostate cancer
Maoping Cai, Xian‐Lu Song, Xinan Li, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100962-100962
Open Access | Times Cited: 126
ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
Priyanka Verma, Yeqiao Zhou, Zhendong Cao, et al.
Nature Cell Biology (2021) Vol. 23, Iss. 2, pp. 160-171
Open Access | Times Cited: 122
CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1-529aa protein and regulating PRDX2 protein stability
Yu Zhang, Jiajia Jiang, Jiayin Zhang, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 115
Page 1 - Next Page

Scroll to top